# Economic Evaluation of New MDR TB Regimens

> **NCT04207112** · PHASE2,PHASE3 · COMPLETED · sponsor: **Medecins Sans Frontieres, Netherlands** · enrollment: 73 (actual)

## Conditions studied

- Multi-drug Resistant Tuberculosis
- Extensively Drug-Resistant Tuberculosis
- Pulmonary Tuberculoses

## Interventions

- **DRUG:** Bedaquiline
- **DRUG:** Pretomanid
- **DRUG:** Moxifloxacin
- **DRUG:** Linezolid
- **DRUG:** Clofazimine
- **DRUG:** Standard Drugs

## Key facts

- **NCT ID:** NCT04207112
- **Lead sponsor:** Medecins Sans Frontieres, Netherlands
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-20
- **Primary completion:** 2022-08-25
- **Final completion:** 2022-08-25
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2024-04-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04207112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04207112, "Economic Evaluation of New MDR TB Regimens". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04207112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*